Meta-analysis confirms a single dose of THC induces psychotic, negative, and other psychiatric symptoms with large effect sizes
A meta-analysis of 15 controlled studies found that a single administration of THC significantly increased psychotic symptoms (effect size 0.91), negative symptoms (0.78), and total psychiatric symptoms (1.10) in healthy people, while CBD showed no consistent moderating effect.
Quick Facts
What This Study Found
THC produced large effect sizes for total symptoms (SMC 1.10), positive/psychotic symptoms (SMC 0.91), and negative symptoms (SMC 0.78) compared to placebo. Of four studies examining CBD's ability to moderate THC effects, only one found a significant reduction.
Key Numbers
Total symptoms: SMC 1.10 (95% CI 0.92-1.28, p<0.0001) in 196 participants. Positive symptoms: SMC 0.91 (95% CI 0.68-1.14, p<0.0001) in 324 participants. Negative symptoms: SMC 0.78 (95% CI 0.59-0.97, p<0.0001) in 267 participants.
How They Did This
Systematic review and meta-analysis of within-person crossover studies administering THC (IV, oral, or nasal) and placebo to healthy participants, with psychiatric symptoms measured by BPRS or PANSS. 15 THC studies and 4 CBD+THC studies were included.
Why This Research Matters
This is the most comprehensive meta-analysis of controlled THC administration studies, providing definitive effect size estimates for THC-induced psychiatric symptoms and finding no consistent evidence that CBD protects against these effects.
The Bigger Picture
The large effect sizes across all symptom domains confirm that THC is a potent psychotomimetic, while the lack of consistent CBD protection challenges the assumption that balanced THC:CBD products are inherently safer for psychiatric risk.
What This Study Doesn't Tell Us
Most studies used intravenous THC, which does not replicate typical cannabis use. Participants were healthy volunteers, not people at high risk for psychosis. Studies of CBD moderation were few (only 4) and heterogeneous.
Questions This Raises
- ?Why did CBD not consistently moderate THC effects?
- ?Would higher CBD doses be needed?
- ?Do these acute laboratory effects translate to real-world psychiatric risk from cannabis use?
Trust & Context
- Key Stat:
- THC effect size for psychotic symptoms: 0.91 (large)
- Evidence Grade:
- Strong: systematic review and meta-analysis of controlled within-person crossover studies, published in The Lancet Psychiatry.
- Study Age:
- Published in 2020 in The Lancet Psychiatry.
- Original Title:
- Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.
- Published In:
- The lancet. Psychiatry, 7(4), 344-353 (2020)
- Authors:
- Hindley, Guy(2), Beck, Katherine, Borgan, Faith, Ginestet, Cedric E, McCutcheon, Robert, Kleinloog, Daniel, Ganesh, Suhas, Radhakrishnan, Rajiv, D'Souza, Deepak Cyril, Howes, Oliver D
- Database ID:
- RTHC-02610
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
How significant are these effect sizes?
All effect sizes were classified as large (above 0.8). For context, this means THC's effect on psychiatric symptoms is substantial and clinically meaningful, not a subtle statistical finding.
Does CBD protect against THC-induced psychosis?
Based on the four available studies, there was no consistent evidence that CBD moderates THC-induced psychiatric symptoms. Only one of four studies found a significant protective effect.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-02610APA
Hindley, Guy; Beck, Katherine; Borgan, Faith; Ginestet, Cedric E; McCutcheon, Robert; Kleinloog, Daniel; Ganesh, Suhas; Radhakrishnan, Rajiv; D'Souza, Deepak Cyril; Howes, Oliver D. (2020). Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.. The lancet. Psychiatry, 7(4), 344-353. https://doi.org/10.1016/S2215-0366(20)30074-2
MLA
Hindley, Guy, et al. "Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.." The lancet. Psychiatry, 2020. https://doi.org/10.1016/S2215-0366(20)30074-2
RethinkTHC
RethinkTHC Research Database. "Psychiatric symptoms caused by cannabis constituents: a syst..." RTHC-02610. Retrieved from https://rethinkthc.com/research/hindley-2020-psychiatric-symptoms-caused-by
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.